| Indo Count is poised for a healthy volume recovery in FY24E. Buy for target price of Rs 295 (25% upside) | |
| Company: | Indo Count Industries |
| Brokerage: | ICICI-Direct |
| Date of report: | August 21, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 25% |
| Summary: | Government initiatives like signing of FTAs with multiple countries & stability in export incentive policy to provide robust opportunities for Indian exporters. ICIL through its sizeable capacity is well poised to capture the export opportunity in global home textile trade |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | ICICI-Direct, Indo Count |
| 25 POWER PACKED PSU PICKS for up to 46% upside in 3-6 months by LKP Securities | |
| Company: | PSU Stocks |
| Brokerage: | LKP Securities |
| Date of report: | August 14, 2023 |
| Type of Report: | Initiating Coverage, Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 46% |
| Summary: | While many of them would have generated positive returns for shareholders over the past two years, their immense potential towards value creation and value migration is yet to unfold going forward |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | BFSI, Bharat Electronics, Canara Bank, CMP, LKP Securities, PSU Stocks |
| ITC’s valuation is inexpensive at ~24x FY25E EPS given the double-digit earnings CAGR: Nirmal Bang | |
| Company: | ITC Ltd |
| Brokerage: | Nirmal Bang |
| Date of report: | August 15, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 16% |
| Summary: | We view the value unlocking from the Hotel business demerger as a welcome move, especially if it is eventually followed by the demerger of the Other FMCG and IT Services businesses as well. If the same fructifies, re-rating will be sharper going forward. Maintain BUY |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | ITC, Nirmal Bang |
| Divi’s Laboratories Ltd is strategically poised to capitalize on emerging opportunities. Buy for target price Rs 4041: SMIFS | |
| Company: | Divi's Lab |
| Brokerage: | SMIFS |
| Date of report: | August 14, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 8.3% |
| Summary: | Divi is strategically poised to capitalize on emerging opportunities presented by recently off-patent molecules. Company is seeing softening of RM and logistics costs which will improve the margins further. We forecast Revenue / EBITDA / PAT CAGR during FY23- 25E at 16.7%/31.5%/27.5%. We value the stock based on SOTP valuation strategy and arrive at a target price of INR 4,041. Accumulate |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Divi's Labs, SMIFS |
| Long term upside targets for Nifty remains intact. Present downward correction is a buying opportunity: HDFC Sec | |
| Company: | Nifty |
| Brokerage: | HDFC Sec |
| Date of report: | August 12, 2023 |
| Type of Report: | Techno-Funda |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | The long term upside targets for Nifty remains intact. Present downward correction is expected to be a buying opportunity. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | HDFC Sec |
| Sagar Cement Poised for a healthy uptick in operational performance. Buy for target price of Rs 305 (29% upside): ICICI Direct | |
| Company: | Sagar Cements |
| Brokerage: | ICICI-Direct |
| Date of report: | August 7, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 29% |
| Summary: | Sagar Cement is trading at attractive valuations (US$ 50/t vs. replacement cost of US$ 110/t). We believe Sagar Cement is an attractive regional play in the southern cement markets and has demonstrated the ability to be one of the lowest cost producers. Hence, we ascribe BUY rating on the stock. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | ICICI-Direct, Sagar Cements |
| PSP Projects is on a strong growth trajectory! Buy for target price of Rs 975 (25% upside): ICICI Direct | |
| Company: | PSP Projects Ltd |
| Brokerage: | ICICI-Direct |
| Date of report: | July 31, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 25% |
| Summary: | PSP is well placed for healthy growth at decent margins to be driven by strong executable order book position. Healthy order inflows secured at FY23 and Q1FY24 coupled with robust bidding pipeline brightens company’s prospects. At the CMP, the company is trading at a valuation of ~12x FY25E P/E |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | ICICI-Direct, PSP Projects Ltd |
| SBI has healthy growth prospects and consistent asset quality. Buy for target price of Rs 729 (28% upside): Bob Caps | |
| Company: | SBI |
| Brokerage: | BOB Capital |
| Date of report: | August 7, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 28% |
| Summary: | Given healthy growth prospects and consistent asset quality, we maintain BUY for an unchanged TP of Rs 729, based on 1.3x FY25E ABV (Gordon Growth Model) and adding in Rs 166/sh for subsidiaries |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | BOB Capital Markets, SBI |
| Ajanta Pharma is a focused player in branded generics. Buy for target price Rs 1950 (26% upside) | |
| Company: | Ajanta Pharma |
| Brokerage: | ICICI-Direct |
| Date of report: | August 28, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 26% |
| Summary: | Ajanta Pharma is a focused player in branded generics, which constitutes ~72% of overall sales, spread across geographies including India. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Ajanta Pharma, ICICI-Direct |